Immunosuppressive treatment for proliferative lupus nephritis.
CONCLUSIONS: In this review update, studies assessing treatment for proliferative lupus nephritis were not designed to assess death (all causes) or ESKD. MMF may lead to increased complete disease remission compared with IV cyclophosphamide, with an acceptable adverse event profile, although evidence certainty was low and included the possibility of no difference. Calcineurin combined with lower dose MMF may improve induction of disease remission compared with IV cyclophosphamide, but the comparative safety profile of these therapies is uncertain. Azathioprine may increase disease relapse as maintenance therapy compared with MMF.
PMID: 29957821 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tunnicliffe DJ, Palmer SC, Henderson L, Masson P, Craig JC, Tong A, Singh-Grewal D, Flanc RS, Roberts MA, Webster AC, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research
More News: Alopecia | Children | Clinical Trials | Conferences | Corticosteroid Therapy | Databases & Libraries | Diarrhoea | General Medicine | Kidney Transplant | Kidney Transplantation | Lupus | Nephritis | Ovaries | Pediatrics | Prograf | Study | Tacrolimus | Toxicology | Transplant Surgery | Transplants | Urology & Nephrology